Lina He

2.9k total citations · 1 hit paper
52 papers, 2.2k citations indexed

About

Lina He is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Lina He has authored 52 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 15 papers in Molecular Biology and 12 papers in Immunology. Recurrent topics in Lina He's work include Cancer Immunotherapy and Biomarkers (14 papers), Immunotherapy and Immune Responses (6 papers) and Lung Cancer Treatments and Mutations (6 papers). Lina He is often cited by papers focused on Cancer Immunotherapy and Biomarkers (14 papers), Immunotherapy and Immune Responses (6 papers) and Lung Cancer Treatments and Mutations (6 papers). Lina He collaborates with scholars based in China, United States and Hong Kong. Lina He's co-authors include Xiaohong Chen, Weibo Cai, Corrine R. Davis, Zhuang Liu, Hongjie Dai, Kai Chen, Zibo Li, Qizhen Cao, Hui Wang and Albert C. Koong and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and SHILAP Revista de lepidopterología.

In The Last Decade

Lina He

49 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Circulation and long-term fate of functionalized, biocompatible single-walled carbon nanotubes in mice probed by Raman spectroscopy

2008 905 citations Weibo Cai, Lina He et al. profile →

Peers

Countries citing papers authored by Lina He

Since Specialization

Citations

This map shows the geographic impact of Lina He's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lina He with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lina He more than expected).

Fields of papers citing papers by Lina He

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lina He. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lina He. The network helps show where Lina He may publish in the future.

Co-authorship network of co-authors of Lina He

This figure shows the co-authorship network connecting the top 25 collaborators of Lina He. A scholar is included among the top collaborators of Lina He based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lina He. Lina He is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Immunotherapy With Programmed Cell Death 1 Versus Programmed Cell Death Ligand 1 Inhibitors in Patients With Advanced Non–Small Cell Lung Cancers: A Multicenter, Retrospective Analysis 2025 ·MedComm ·(unknown), (unknown), Tao Chang, Juan Wang, (unknown), (unknown), (unknown), Wenjun Meng, Yalun Li, Lina He, (unknown), Yan Zeng, Bojiang Chen, Weimin Li	0
2	Long non-coding RNA NEAT1 promotes ovarian granulosa cell proliferation and cell cycle progression via the miR-29a-3p/IGF1 axis 2025 ·Journal of Ovarian Research ·Lina He, Jie Lin, (unknown), (unknown), Hao Li, Yanhong Fu, Ran Xu, Wei Chen	1
3	Fangchinoline-mediated autophagy inhibition amplifies antigen presentation and PD-1 blockade efficacy in lung cancer 2025 ·Acta Pharmacologica Sinica ·Yue Song, Yu Jiang, (unknown), (unknown), Mei Xu, (unknown), Lina He, Zhongxia Ren, Yuan Liao, Fang Liu, Yanjun Jiang, Shan Hu, Wei Guo, (unknown), Xiaoyi Liu, Jian Gu, Yafei Shi, Huanhuan Luo, Kun Wang, Jianyong Xiao	2
4	Predictive strategies for oocyte maturation in IVF cycles: from single indicators to integrated models 2024 ·Middle East Fertility Society Journal ·Lina He, (unknown), Jie Lin, Yi Liu, Wei Chen	1
5	RPS 2.0: an updated database of RNAs involved in liquid–liquid phase separation 2024 ·Nucleic Acids Research ·(unknown), (unknown), Tianjian Chen, Qi Jiang, Luowanyue Zhang, Lina He, Jian Zheng, An Zhao, Jian Ren, Zhixiang Zuo	1
6	STK11/LKB1-Deficient Phenotype Rather Than Mutation Diminishes Immunotherapy Efficacy and Represents STING/Type I Interferon/CD8+ T-Cell Dysfunction in NSCLC 2023 ·Journal of Thoracic Oncology ·Anlin Li, (unknown), Zhixin Yu, Zihui Tan, Lina He, Sha Fu, Mengting Shi, (unknown), (unknown), Zhichao Li, Jiaqing Liu, Yixin Zhou, Wenfeng Fang, Yunpeng Yang, Li Zhang, Shaodong Hong	21
7	Impact of prophylactic dexamethasone on the efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy in patients with advanced Non-Squamous Non-Small-Cell lung cancer 2023 ·International Immunopharmacology ·Hui Yu, Jingyu Chen, Yixin Zhou, Sheng Jin, Xuanye Zhang, Lina He, Likun Chen, Qian Chu, Zhang Li, (unknown)	7
8	Adverse Event Reporting Quality in Cancer Clinical Trials Evaluating Immune Checkpoint Inhibitor Therapy: A Systematic Review 2022 ·Frontiers in Immunology ·Yuhong Wang, Chen Chen, Wei Du, Yixin Zhou, Lina He, Shaodong Hong, Li Zhang	6
9	Unsatisfied Reporting Quality of Clinical Trials Evaluating Immune Checkpoint Inhibitor Therapy in Cancer 2021 ·Frontiers in Immunology ·Chen Chen, Yixin Zhou, Xuanye Zhang, Yuhong Wang, Lina He, Zuan Lin, (unknown), (unknown), Shaodong Hong, Li Zhang	1
10	PD-1/PD-L1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in first-line treatment for non-squamous non-small-cell lung cancer 2021 ·Journal for ImmunoTherapy of Cancer ·Hui Yu, Ping Chen, Liangping Xia, Sha Fu, Chen Chen, Xuanye Zhang, Lina He, Bei Zhang, Yixin Zhou, Shaodong Hong	10
11	Tanshinone IIA protects human coronary artery endothelial cells from ferroptosis by activating the NRF2 pathway 2021 ·Biochemical and Biophysical Research Communications ·Lina He, Yingyi Liu, Kun Wang, Chengxi Li, Weibin Zhang, Zhenzhen Li, Xianzhang Huang, Yujuan Xiong	58
12	Hepatotoxicity associated with PD-1 blockade antibodies in cancer patients co-infected with hepatitis B virus 2021 ·Cancer Immunology Immunotherapy ·Zuan Lin, Xuanye Zhang, Yixin Zhou, Chen Chen, Lina He, Haifeng Li, Yuhong Wang, Tao Chen, Shaodong Hong, Li Zhang	13
13	Generation of induced pluripotent stem cell GZHMCi001-A and GZHMCi001-B derived from peripheral blood mononuclear cells of epileptic patients with KCNC1 mutation 2020 ·Stem Cell Research ·(unknown), (unknown), Yingjun Xie, Yi Cheng, Lina He, Diyu Chen, Yinghong Yang, Bing Song, Xiaofang Sun	4
14	Pretreatment biomarkers as prognostic predictors of survival in patients with Pancreatic Cancer treated with Gemcitabine-based Therapy and 5-Fluorouracil: Neutrophil-to-lymphocyte ratio vs Platelet-to-lymphocyte ratio 2020 ·International Journal of Medical Sciences ·(unknown), Yuan Liao, (unknown), Lina He, (unknown), (unknown), (unknown), Qing Xia	5
15	The efficacy of neoadjuvant chemotherapy in different histological types of cervical cancer 2014 ·Gynecologic Oncology ·Lina He, (unknown), (unknown), Wen-Fei Wei, Liang Li, Lingfei Han, Mehdi Kebria, Ping Liu, Chunlin Chen, Yanhong Yu, Mei Zhong, Wei Wang	44
16	Integrin-targeted imaging and therapy with RGD4C-TNF fusion protein 2008 ·Molecular Cancer Therapeutics ·Hui Wang, Kai Chen, Weibo Cai, Zibo Li, Lina He, Amir Kashefi, Xiaohong Chen	45
17	Evaluation of biodistribution and anti-tumor effect of a dimeric RGD peptide–paclitaxel conjugate in mice with breast cancer 2008 ·European Journal of Nuclear Medicine and Molecular Imaging ·Qizhen Cao, Zibo Li, Kai Chen, Zhanhong Wu, Lina He, Nouri Neamati, Xiaohong Chen	67
18	PET imaging of acute and chronic inflammation in living mice 2007 ·European Journal of Nuclear Medicine and Molecular Imaging ·Qizhen Cao, Weibo Cai, Zibo Li, Kai Chen, Lina He, (unknown), Mizhou Hui, Xiaohong Chen	52
19	Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody 2007 ·European Journal of Nuclear Medicine and Molecular Imaging ·Weibo Cai, Kai Chen, Lina He, Qizhen Cao, Albert C. Koong, Xiaohong Chen	203
20	18F-labeled mini-PEG spacered RGD dimer (18F-FPRGD2): synthesis and microPET imaging of αvβ3 integrin expression 2007 ·European Journal of Nuclear Medicine and Molecular Imaging ·Zhanhong Wu, Zibo Li, Weibo Cai, Lina He, Frederick T. Chin, Fang Li, Xiaohong Chen	109

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact